211 related articles for article (PubMed ID: 12755697)
41. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.
Meyer P; Prodromou C; Liao C; Hu B; Mark Roe S; Vaughan CK; Vlasic I; Panaretou B; Piper PW; Pearl LH
EMBO J; 2004 Feb; 23(3):511-9. PubMed ID: 14739935
[TBL] [Abstract][Full Text] [Related]
42. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Li J; Soroka J; Buchner J
Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
[TBL] [Abstract][Full Text] [Related]
43. An unstructured C-terminal region of the Hsp90 co-chaperone p23 is important for its chaperone function.
Weikl T; Abelmann K; Buchner J
J Mol Biol; 1999 Oct; 293(3):685-91. PubMed ID: 10543959
[TBL] [Abstract][Full Text] [Related]
44. NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol.
Dehner A; Furrer J; Richter K; Schuster I; Buchner J; Kessler H
Chembiochem; 2003 Sep; 4(9):870-7. PubMed ID: 12964162
[TBL] [Abstract][Full Text] [Related]
45. Mechanistic Asymmetry in Hsp90 Dimers.
Flynn JM; Mishra P; Bolon DN
J Mol Biol; 2015 Sep; 427(18):2904-11. PubMed ID: 25843003
[TBL] [Abstract][Full Text] [Related]
46. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones.
Prodromou C; Siligardi G; O'Brien R; Woolfson DN; Regan L; Panaretou B; Ladbury JE; Piper PW; Pearl LH
EMBO J; 1999 Feb; 18(3):754-62. PubMed ID: 9927435
[TBL] [Abstract][Full Text] [Related]
47. Crystal structure of the middle and C-terminal domains of Hsp90α labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target.
Peng S; Woodruff J; Pathak PK; Matts RL; Deng J
Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):571-585. PubMed ID: 35503206
[TBL] [Abstract][Full Text] [Related]
48. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.
Meyer P; Prodromou C; Liao C; Hu B; Roe SM; Vaughan CK; Vlasic I; Panaretou B; Piper PW; Pearl LH
EMBO J; 2004 Mar; 23(6):1402-10. PubMed ID: 15039704
[TBL] [Abstract][Full Text] [Related]
49. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
[TBL] [Abstract][Full Text] [Related]
50. N-terminal domain of human Hsp90 triggers binding to the cochaperone p23.
Karagöz GE; Duarte AM; Ippel H; Uetrecht C; Sinnige T; van Rosmalen M; Hausmann J; Heck AJ; Boelens R; Rüdiger SG
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):580-5. PubMed ID: 21183720
[TBL] [Abstract][Full Text] [Related]
51. Dynamic nucleotide-dependent interactions of cysteine- and histidine-rich domain (CHORD)-containing Hsp90 cochaperones Chp-1 and melusin with cochaperones PP5 and Sgt1.
Hong TJ; Kim S; Wi AR; Lee P; Kang M; Jeong JH; Hahn JS
J Biol Chem; 2013 Jan; 288(1):215-22. PubMed ID: 23184943
[TBL] [Abstract][Full Text] [Related]
52. Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90.
Cunningham CN; Krukenberg KA; Agard DA
J Biol Chem; 2008 Jul; 283(30):21170-8. PubMed ID: 18492664
[TBL] [Abstract][Full Text] [Related]
53. Nucleotide-dependent interaction of Saccharomyces cerevisiae Hsp90 with the cochaperone proteins Sti1, Cpr6, and Sba1.
Johnson JL; Halas A; Flom G
Mol Cell Biol; 2007 Jan; 27(2):768-76. PubMed ID: 17101799
[TBL] [Abstract][Full Text] [Related]
54. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
55. Both the N- and C-terminal chaperone sites of Hsp90 participate in protein refolding.
Minami M; Nakamura M; Emori Y; Minami Y
Eur J Biochem; 2001 Apr; 268(8):2520-4. PubMed ID: 11298772
[TBL] [Abstract][Full Text] [Related]
56. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease.
Khalid S; Paul S
Med Hypotheses; 2014 Jul; 83(1):39-46. PubMed ID: 24785461
[TBL] [Abstract][Full Text] [Related]
57. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform.
McLaughlin SH; Ventouras LA; Lobbezoo B; Jackson SE
J Mol Biol; 2004 Nov; 344(3):813-26. PubMed ID: 15533447
[TBL] [Abstract][Full Text] [Related]
58. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
59. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
60. Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding.
Rosser MF; Nicchitta CV
J Biol Chem; 2000 Jul; 275(30):22798-805. PubMed ID: 10816561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
